StockCIK 1674416

CRISPR Therapeutics AG (CRSP): Insider Trades and Fund Holdings

In the past 12 months, CRISPR Therapeutics AG insiders reported 0 open-market purchases worth $0 and 7 sales worth $4.88M; 3 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$4.88MSold by insiders, 12 months

0Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 20, 2026.

Recent CRSP insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 20	Oct 19	Samarth KulkarniCEO	CEO	▼ SELL	47,837	49.78	$2.38M	−13%	Form 4 ↗
Oct 16	Oct 14	Simeon GeorgeDirector	Director	▼ SELL10b5-1	14,514	49.63	$720K	−48%	Form 4 ↗
Oct 15	Oct 14	Samarth KulkarniCEO	CEO	▼ SELL	4,098	49.26	$202K	−1.6%	Form 4 ↗
Oct 15	Oct 14	James R. KasingerGeneral Counsel	General Counsel	▼ SELL	1,040	49.26	$51K	−1.1%	Form 4 ↗
Oct 8	Oct 6	James R. KasingerGeneral Counsel	General Counsel	▼ SELL10b5-1	1,990	60.04	$119K	−2.1%	Form 4 ↗
Sep 24	Sep 22	James R. KasingerGeneral Counsel	General Counsel	▼ SELL10b5-1	10,400	60.24	$626K	−9.9%	Form 4 ↗
Sep 21	Sep 17	Ali BehbahaniDirector	Director	▼ SELL	13,679	57.09	$781K	−45%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Bought	Sells	Sold	Latest
Samarth Kulkarni	CEO	$0	2	$2.58M	Oct 20, 2026
Simeon George	Director	$0	1	$720K	Oct 16, 2026
James R. Kasinger	General Counsel	$0	3	$797K	Oct 15, 2026
Ali Behbahani	Director	$0	1	$781K	Sep 21, 2026

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →